文献速递系统性红斑狼疮

狼疮肾炎组织病理学生物标志物:现状综述

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?
PubMed 文献 · Arthritis Rheumatol · 2026-01-28

该综述系统检索2012至2024年成人活检证实的狼疮肾炎研究,评估生物标志物与组织病理学指标的相关性。质量合格研究中识别出TGF-β1、PTX3、CD163、CD11b和IL-16五种潜在可用标志物,但方法学异质性阻碍临床转化。

要点

  • 68%的研究质量评分为弱或极弱(评分<5,量表2-9)。
  • 质量合格研究中识别出五种潜在可用生物标志物:TGF-β1、PTX3、CD163、CD11b、IL-16。
  • 方法学异质性和总体中等研究质量是生物标志物临床转化的障碍。

核心结论

  • 研究间方法学异质性和文章质量的总体中等评分阻碍了新生物标志物进入临床实践。
  • 狼疮肾炎工作组倡导进一步研究那些能良好反映特定组织病理学特征且优于传统检测的选定生物标志物。
  • 目前符合上述标准的生物标志物选择非常有限。

研究设计与样本

  • 系统文献检索纳入2012至2024年发表的成人活检证实狼疮肾炎研究。
  • 检索聚焦于展示生物标志物与组织学发现相关性的研究,特别是NIH活动性和慢性指数、ISN/RPS组织学分类及特定活动和慢性病变。
  • 由多学科专家组使用标准化评分系统评估所选文章质量。

主要发现

  • 质量评估中68%的文章为弱或极弱(评分<5,量表2-9)。
  • 从剩余合格或稳健文章中识别出五种潜在可临床实施的生物标志物:转化生长因子β1、五聚素-3、(可溶性)CD163、CD11b和白细胞介素-16。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify noninvasive biomarkers. By reviewing and critically assessing the quality of existing studies on LN biomarkers correlating with histopathology, we here explore the challenges in promoting their use in clinical practice and identify promising candidates for future validation. METHODS: A systematic literature search was conducted, including studies on adult patients with biopsy-proven LN published between 2012 and 2024. The search focused on studies demonstrating correlations between biomarkers and histologic findings, particularly the National Institutes of Health activity and chronicity indices, the International Society of Nephrology/Renal Pathology Society histologic classes, and specific active and chronic lesions. The quality of selected articles was assessed by a multidisciplinary panel of experts using a standardized scoring system. RESULTS: Ninety-three articles investigating the potential utility of >100 biomarkers were selected. In quality assessment, 68% of the articles were weak or very weak (score <5, scale 2-9). From the remaining articles (adequate or robust) we identified five biomarkers with a potential for implementation in clinical practice: transforming growth factor β1, pentraxin-3, (soluble) CD163, CD11b, and interleukin-16. CONCLUSION: The methodologic heterogeneity across studies and the overall moderate score of the quality of the articles represent obstacles to the implementation of new biomarkers into clinical practice. The LN working group advocates further research on selected biomarkers that demonstrated good capacity to reflect specific histopathologic features outperforming traditional tests. At present, the choice of biomarkers that perform to these standards is very limited.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Querin V, Palazzo L, Fogo AB, et al. Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand? Arthritis Rheumatol. 2026. PMID: 41169181. doi:10.1002/art.43427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。